Our findings support the existence of a novel feedback loop U2AF65/circNCAPG/RREB1 that promotes malignant progression in GSCs and could be a novel therapeutic target for glioma patients.
The U2AF65/circNCAPG/RREB1 feedback loop promotes malignant phenotypes of glioma stem cells through activating the TGF-beta pathway.